Ataxia in institutionalized patients with epilepsy

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Epilepsy is a chronic neurological disorder affecting millions worldwide.
• Anticonvulsant medications, such as phenytoin, are commonly used for epilepsy management.
• Long-term institutionalization and medication use can present unique patient challenges.

Purpose of the Study:

• To investigate the prevalence of gait ataxia in chronically institutionalized adult epilepsy patients.
• To explore the correlation between gait ataxia, cerebellar atrophy, and phenytoin levels.
• To identify risk factors associated with cerebellar atrophy in this patient population.

Main Methods:

• Gait analysis (stride width) was performed on 41 chronically institutionalized adult epilepsy patients.
• Serum phenytoin levels, seizure frequency, and history of toxicity were recorded.
• Computed tomographic (CT) head scans were obtained for 17 patients to assess for cerebellar atrophy.

Main Results:

• 54% of patients exhibited gait ataxia (wide stride width).
• Patients with cerebellar atrophy showed wider stride width, later seizure onset, and higher peak phenytoin levels.
• Gait ataxia was inconsistently associated with cerebellar atrophy.
• No correlation was found between stride width and serum phenytoin, seizure frequency, or status epilepticus.

Conclusions:

• Elevated serum phenytoin concentrations may be a risk factor for cerebellar atrophy in epilepsy patients.
• Cerebellar atrophy is linked to gait ataxia and higher phenytoin exposure.
• Seizure frequency and status epilepticus do not appear to be independent risk factors for cerebellar atrophy.